RESUMO
Antecedentes: la enfermedad de Fabry (Ef) es una enfermedad rara ligada a X secundaria al depósito lisosomal de glicoesfingolípidos, debido a la deficiencia de la enzima alfa galactosidasa A (α-Gal A). A pesar de su baja frecuencia, es una condición que afecta la calidad de vida de los pacientes y disminuye su esperanza de vida. Objetivo: generar recomendaciones informadas para el diagnóstico y tratamiento de pacientes pediátricos (menores de 18 años) con Ef. Material y Métodos: revisión de literatura en bases de datos y literatura gris a partir de 2010, incluyendo guías de práctica clínica, revisiones sistemáticas y estudios primarios. La calidad de evidencia se evaluó de acuerdo con el tipo. Las recomendaciones se sometieron a consenso de expertos a través de metodología Delphi modificada. El acuerdo se definió a partir del 80 %. Resultados: A partir del análisis de la evidencia recolectada se formularon un total de 45 recomendaciones para tamización, diagnóstico y tratamiento de paciente pediátrico con Ef. El panel revisor estuvo conformado por once expertos en el tema. Las recomendaciones fueron aprobadas con puntuaciones entre 82.3 % y 100 %. Conclusiones: las recomendaciones resultantes del consenso de expertos permitirán la toma de decisiones clínicas y estandarización de la práctica en la atención de pacientes pediátricos con Ef en el país y la región. El diagnóstico temprano y oportuno garantiza una disminución del impacto en la calidad de vida de los pacientes y sus familiares
Background: Fabry disease (fD) is a rare X-linked disease characterized by the accumulation of glyco- sphingolipids in lysosomes due to the deficiency in the production of alpha-galactosidase A (α-Gal A) enzyme. Despite its low frequency, this disease has a serious impact on the life expectancy and quality. Objective: To make evidence-based recommendations for the diagnosis and treatment of fD in pediatric patients (<18 years of age). Materials and Methods: A study of databases and gray literature was conducted in 2010, including clinical practice guidelines, systematic reviews, and primary research. The type of evidence was used to determine the quality of evidence. The recommendations were submitted to an expert consensus using the modified Delphi process. The agreement was set at 80%. Conclusions: The recommendations emerging from this expert consensus will enable the standardization of care provision for pediatric patients with fD in Colombia and Latin America and clinical decision-making for disease management. Notably, making an early diagnosis ensures a reduction in the impact of this disease on the quality of life of patients and their families
Fundamento: a doença de Fabry (Df) é uma rara doença ligada ao cromossomo X secundária à deposi- ção lisossômica de glicoesfingolipídeos devido à deficiência da enzima alfa galactosidase A (α-Gal A). Apesar de sua baixa frequência, é uma condição que afeta a qualidade de vida dos pacientes e diminui sua expectativa de vida. Objetivo: gerar recomendações baseadas em evidências para o diagnóstico e tratamento de pacientes pediátricos (com menos de 8 anos de idade) com Df. Materais e Métodos: foi realizada uma revisão da literatura em bases de dados e literatura cinza a partir de 2010, incluindo diretrizes de prática clínica, revisões sistemáticas e estudos primários. A qualidade da evidência foi avaliada de acordo com o tipo de evidência. As recomendações foram submetidas ao consenso de especialistas usando a metodologia Delphi modificada. A concordância foi definida a partir de 80%. Resultados: com base na análise das evidências coletadas, foram formuladas um total de 45 recomendações para triagem, diagnóstico e tratamento de pacientes pediátricos com doença de Fabry. O painel de revisão foi composto por onze especialistas no assunto. As recomendações foram aprovadas com pontuações entre 82,3% e 100%. Conclusões: as recomendações resultantes do consenso de especialistas permitirão a tomada de decisão clínica e a padronização da prática no cuidado de pacientes pediátricos com Df em nível nacional e regional; o diagnóstico precoce e oportuno garante a redução do impacto na qualidade de vida dos pacientes e seus familiares.
Assuntos
HumanosRESUMO
BACKGROUND: Fabry disease (FD) is a hereditary X-linked metabolic storage disorder characterized by deficient or absent lysosomal α-galactosidase A (α-Gal A) activity. This deficiency causes progressive accumulation of glycosphingolipids, primarily globotriaosylceramide (Gb3), in nearly all organ systems. Gastrointestinal (GI) symptoms can be very debilitating and are among the most frequent and earliest of the disease. As the pathophysiology of these symptoms is poorly understood, we carried out a morphological and molecular characterization of the GI tract in α-Gal A knockout mice colon in order to reveal the underlying mechanisms. METHODS: Here, we performed the first morphological and biomolecular characterization of the colon wall structure in the GI tract of the α-Gal A knock-out mouse (α-Gal A -/0), a murine model of FD. KEY RESULTS: Our data show a greater thickness of the gastrointestinal wall in α-Gal A (-/0) mice due to enlarged myenteric plexus' ganglia. This change is paralleled by a marked Gb3 accumulation in the gastrointestinal wall and a decreased and scattered pattern of mucosal nerve fibers. CONCLUSIONS AND INFERENCES: The observed alterations are likely to be a leading cause of gut motor dysfunctions experienced by FD patients and imply that the α-Gal A (-/0) male mouse represents a reliable model for translational studies on enteropathic pain and GI symptoms in FD.
Assuntos
Colo/metabolismo , Colo/patologia , Doença de Fabry/metabolismo , Doença de Fabry/patologia , Fibras Nervosas/patologia , Triexosilceramidas/metabolismo , Animais , Citocinas/sangue , Feminino , Masculino , Camundongos , Camundongos Knockout , Plexo Mientérico/metabolismo , Plexo Mientérico/patologia , Triexosilceramidas/genética , Ubiquitina Tiolesterase/genética , alfa-Galactosidase/genéticaRESUMO
La enfermedad de Fabry es una enfermedad rara ligada al X consecuencia de la deficiencia de α-galactosidasa A lisosomal, lo que genera un depósito excesivo de glicoesfingolípidos, predominantemente globotriaosilceramida (Gl3) y mortalidad de causa renal cardíaca y neurológica. El tratamiento actual consiste en la terapia de reemplazo enzimático, lo que intenta reemplazar por vía intravenosa la enzima deficiente. Existen en el mercado europeo y latinoamericano dos formulaciones de agalsidasa: agalsidasa alfa y agalsidasa beta, lo que permite al médico elegir el tratamiento. Sin embargo, la Food and Drug Administration en Estados Unidos rechazó aprobar la agalsidasa alfa. La diferencia fundamental entre agalsidasa alfa y agalsidasa beta es la dosis autorizada: 0,2 mg/kg y 1 mg/kg cada dos semanas respectivamente. Durante años esta diferencia tan grande de dosis sorprendió a los clínicos. Sin embargo varios estudios recientes sugieren que hay un efecto dosis-respuesta y que para algunos pacientes la dosis de 0,2 mg/kg cada dos semanas puede ser insuficiente. Sin embargo, no existen herramientas que permitan predecir que pacientes van a necesitar una dosis más alta para detener o enlentecer la progresión de la enfermedad. En esta revisión resumimos el estado actual del conocimiento sobre el impacto Tratamiento en la enfermedad de Fabry de las diferentes dosis y su eficacia en tratamiento de la enfermedad de Fabry.
Fabry disease is a rare X-linked inherited disorder due to deficient or absent lysosomal α-galactosidase A activity, resulting in an excessive glycosphingolipid deposit, mainly globotriaosylceramide (gl3) and mortality due renal, cardiac and neurological cause. Current treatment available is enzyme replacement therapy, where the deficient enzyme is substituted. In Latinamerica and Europe two different formulations of agalsidase (alfa and beta) are available. Food and Drug Administration in United States did not approve agalsidasa Alfa. The main difference among these formulations is the licensed dose: 0.2 mg/kg every other week for Alfa and 1 mg/kg every other week for Beta. Recent studies suggest a dose-dependent response, making 0.2 mg/kg every other week not sufficient in some patients. However there are no tools to predict which patients need a higher dose for preventing or decreasing the disease progression. This review, summarize the current knowledge about the impact of different dose and its efficacy in Fabry disease.
Assuntos
Masculino , Feminino , Humanos , Dosagem , Ativação Enzimática , Doença de Fabry , Doença de Fabry/terapiaRESUMO
UNLABELLED: In Fabry disease, globotriaocylceramid (GL3) starts to accumulate in kidney cells in utero, and continues to accumulate throughout childhood and adulthood with progressive tissue damage, which may lead to renal failure. MATERIAL AND METHODS: Eight children with classical Fabry disease, median age 12 (range 4-16 years) had a renal biopsy performed before the initiation of enzyme replacement therapy (ERT). All patients were normalbuminuric and had normal GFR. Three patients were re-biopsied after three or five years. RESULTS: In all patients, significant GL3-accumulation was found in several types of kidney cells with high amounts of GL3 in the podocytes. Segmental podocyte foot process effacement was shown in all but two patients; no effacement was seen neither in the youngest male patient at 4 years of age nor in a male aged 12. A 12-year-old female patient had normal podocyte foot processes before the start of ERT, but de novo foot process flattening and unchanged high score of podocyte GL3 accumulation were seen in the re-biopsy after three years of ERT (agalsidase alpha 0.2 mg/kg/every other week). Two boys showed worsening of podocyte effacement in kidney biopsy after five years of agalsidase alpha 0.2 mg/kg/eow. CONCLUSIONS: Podocyte foot process effacement was found in the majority of eight young classical Fabry patients of both genders after the age of 11 years, without clinical signs of Fabry nephropathy. Kidney biopsies are essential in the early diagnosis of nephropathy and in the evaluation of the response to enzyme replacement therapy of early Fabry nephropathy.
Assuntos
Doença de Fabry/complicações , Nefropatias/etiologia , Nefropatias/patologia , Podócitos/patologia , Adolescente , Idade de Início , Albuminúria/etiologia , Criança , Pré-Escolar , Terapia de Reposição de Enzimas , Doença de Fabry/tratamento farmacológico , Doença de Fabry/metabolismo , Feminino , Humanos , Nefropatias/fisiopatologia , Masculino , Microscopia Eletrônica de Transmissão , Mutação , Podócitos/metabolismo , Triexosilceramidas/metabolismo , alfa-Galactosidase/genética , alfa-Galactosidase/uso terapêuticoRESUMO
Las enfermedades por depósito lisosomal (EDL) son un grupo heterogéneo de más de 40 dolencias genéticas, debidas a la deficiencia de diversas enzimas encargadas de metabolizar sustancias dentrode los lisosomas. Estas macromoléculas se depositan dentro de las organelas de múltiples órganos y dan lugar a diversos signos y síntomas.Muchas de estas enfermedades tienen manifestaciones cutáneas, e incluso en algunas oportunidades es el dermatólogo quien sospecha el diagnóstico a partir de las lesiones en piel.En el presente trabajo se describen 8 pacientes con EDL, diagnosticados en nuestro servicio entre 2009 y 2010, en los cuales las lesiones en piel fueron la clave para arribar al diagnóstico.Cinco pacientes presentaban enfermedad de Fabry (un varón y 4 mujeres), uno mucopolisacaridosis 2 (sexo masculino), uno beta-manosidosis (sexo masculino) y el último galactosialidosis (sexo femenino).Los angioqueratomas fueron la manifestación cutánea más frecuente, y la clave diagnóstica en los pacientes con Fabry, el paciente con manosidosis y la paciente con galactosialidosis, mientras que la lesión en piel que llevó a sospechar mucopolisacaridosis 2 fueron manchas mongólicas aberrantes, algunas lenticulares, que comprometían el tronco.En cuatro pacientes el diagnóstico se confirmó por estudios enzimáticos en gota de sangre en papel de filtro, leucocitos y/u orina. En cinco pacientes (uno de los cuales ya había sido diagnosticado deforma bioquímica) se realizó estudio molecular. En todos los pacientes se hicieron los estudios complementarios necesarios para evaluar extensión del compromiso extracutáneo y necesidad de tratamientoespecífico (en aquellos pacientes en los cuales su enfermedad de base dispone de terapia de reemplazo enzimático). En uno de los pacientes con Fabry se inició terapia específica.El interés de nuestro trabajo radica en mostrar distintas EDL en las cuales el rol del dermatólogo fue fundamental para arribar al diagnóstico, resaltando..
Lysosomal-storage disorders are a group of more than 40 heterogeneous hereditary diseases dueto the deficiency of various lysosomal enzymes, in charge of the metabolization of macromolecules,with accumulation of the undigested substances inside those organelles througout severalorgans, deriving in the multiple symptoms and signs of these diseases.A great number of these diseases may have cutaneous lesions, and in many cases the dermatologistmay be the one to suggest the diagnosis.We describe eight patients with lisosomal storage diseases diagnosed at our hospital during 2009and 2010, on whom the cutaneous lesions were the clue to the diagnosis. Five patients were diagnosed as Fabry´s disease (1 male and 4 females), one as mucopolisaccharidosis2 (male), one as mannosidosis (male) and the last one as galactosyalidosis (female). Angiokeratomaswhere the most frequent cutaneous manifestation, and the key to the diagnosis inFabrys, beta mannosidosis and galactosyalidosis, while aberrant and lenticular mongolian spotson the trunk led us to the diagnosis of mucopolissacharidosis 2.On four patients the diagnosis was confirmed by biochemical work-up. On five patients (one ofthem had already been confirmed with biochemistry) a genetic study was also performed.On all the patients studies where performed to evaluate the extension of the systemic disease andthe need of a specific treatment (for those diseases where it is available). One of the patients withFabry´s disease started the treatment soon after the diagnosis.We would like to emphasize the fundamental role of the dermatologist in diagnosing these diseases,stressing not only the academic importance of these rare diseases but also the possibility ofstarting in many of them specific enzyme replacement treatment.
Assuntos
Humanos , Masculino , Adulto , Feminino , Criança , Doenças por Armazenamento dos Lisossomos/diagnóstico , Doenças por Armazenamento dos Lisossomos/metabolismo , Doenças por Armazenamento dos Lisossomos/patologia , Pele/patologia , Angioceratoma/patologia , Aberrações Cromossômicas , Cromossomos Humanos X , Doença de Fabry/metabolismo , Doença de Fabry/patologia , Mucopolissacaridose II/diagnóstico , Mucopolissacaridose II/metabolismo , Mucopolissacaridose II/patologiaRESUMO
INTRODUCTION: Fabry's disease is a consequence of the deficiency of lysosomal alpha-galactosidase A, which gives rise to excessive depositing of glycosphingolipids in endothelial cells, smooth muscle cells in vessels, podocytes, neurons, etc. The symptoms begin in childhood, with neuropathic pain, and progress towards kidney and heart failure, as well as cerebro-vascular accidents from the third decade of life onwards. DEVELOPMENT: This review presents the changes in the pathophysiological concepts that have been acquired in the nine years since enzyme replacement therapy started to be employed. The earlier enzyme replacement is started, the more effective it is, which thereby calls for a review of the criteria for its use in patients. Furthermore, the need for concomitant treatments is also evaluated based on the pathophysiology of the disease. CONCLUSIONS: The joint use of enzyme replacement therapy, antiproteinuric drugs, statins and acetylsalicylic acid must be evaluated as initial treatment in all patients with Fabry's disease.
Assuntos
Doença de Fabry , alfa-Galactosidase/metabolismo , Terapia de Reposição de Enzimas , Doença de Fabry/fisiopatologia , Doença de Fabry/terapia , Glicoesfingolipídeos/metabolismo , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Lisossomos/enzimologia , Óxido Nítrico/metabolismoRESUMO
BACKGROUND AND OBJECTIVE: The lysosomal deposit of sphingolipids secondary to alpha-galactosidase-A deficiency causes Fabry disease. The deposit in the endothelial cells of the vasa nervorum and the small caliber axons, among other structures, results in the characteristic painful neuropathy. It is our objective to present the findings of the neuropathy evaluation before and after 18 months of agalsidase beta enzyme replacement therapy. MATERIALS AND METHOD: A neurological exam, a neurophysiological study measuring sensory and motor conduction velocities and amplitudes and a quantitative sensory testing were performed on 5 patients with confirmed Fabry disease; quantification on pain measurement scales was also done. RESULTS: Prior to treatment, no anomalies were found in the conduction velocities or the compound muscular action potential amplitudes; the quantitative sensory test was abnormal in all patients. After treatment, improvement was seen in the pain scales and the quantitative sensory test. CONCLUSIONS: Enzyme replacement therapy with agalsidase beta demonstrated subjective and objective benefits related to the painful neuropathy of Fabry disease.
Assuntos
Terapia de Reposição de Enzimas , Doença de Fabry/tratamento farmacológico , Isoenzimas/uso terapêutico , alfa-Galactosidase/uso terapêutico , Adolescente , Adulto , Feminino , Humanos , Masculino , Adulto JovemRESUMO
The objective is to analyze the updated evidence on the physiopathological mechanisms that can generate cerebrovascular damage in Fabry disease. Fabry disease is the result of the deficiency of alpha-galactosidasa A, which causes pathological storage of glycosphingolipids, in different cells. Associated to renal and cardiac insufficiency, cerebrovascular complications can derive in the death of the patients. During a long time the only reported mechanism was the vascular occlusion by deposit of lipids at endothelial level. At the present time, other mechanisms are postulated. The arrival of enzyme replacement therapy has generated great expectation on the possibility of reversion of these alterations. Although the evidence is scarce and more long-term studies are necessary, some reports demonstrate that after months, the treatment has managed to revert some of the mechanisms involved.
Assuntos
Doença de Fabry/fisiopatologia , Acidente Vascular Cerebral/fisiopatologia , Velocidade do Fluxo Sanguíneo , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Encéfalo/fisiopatologia , Constrição Patológica/fisiopatologia , Dilatação Patológica/fisiopatologia , Endotélio Vascular/fisiopatologia , Doença de Fabry/complicações , Doença de Fabry/patologia , Glicoesfingolipídeos/metabolismo , Humanos , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/patologia , Trombofilia/fisiopatologiaRESUMO
Se analiza la evidencia existente a la fecha sobre los mecanismos fisiopatológicos que puedem generar accidentes cerebrovasculares en la enfermedad de Fabry. Esta entidad es el resultado de la deficiencia de alfa-galactosidasa A, lo que resulta en depósito patológico de glicoesfingilípidos en distintas poblaciones celulares. Asociados a la insuficiencia renal y cardíaca, los accidentes cerebrovasculares pueden derivar en la muerte de los pacientes. Durante mucho tiempo el único mecanismo generador de daño vascular informado fue la oclusión vascular por depósito lipídico a nivel endotelial. En la actualidad se describen otros mecanismos. El advenimento de la terapia de reemplazo enzimático ha generado gran expectativa en cuanto la posibilidad de reversión de estos mecanismos. Si bien la evidencia es escasa y son necesarios más estudios a largo plazo, algunos informes demuestran que luego de meses, el tratamiento ha logrado revertir algunos de los mecanismos implicados
The objective is to analyze the updated evidence on the physiopathological mechanisms that can generate cerebrovascular damage in Fabry disease. Fabry disease is the result of the deficiency of alpha-galactosidasa A, which causes pathological storage of glycosphingolipids, in different cells. Associated to renal and cardiac insufficiency, cerebrovascular complications can derive in the death of the patients. During a long time the only reported mechanism was the vascular occlusion by deposit of lipids at endothelial level. At the present time, other mechanisms are postulated. The arrival of enzyme replacement therapy has generated great expectation on the possibility of reversion of these alterations. Although the evidence is scarce and more long-term studies are necessary, some reports demonstrate that after months, the treatment has managed to revert some of the mechanisms involved